FOXC2 and breast carcinoma: Samples (n = 270) were evaluated from the tumors of patients with breast cancer; 186 samples were from stage T1-T2 tumors, 84 samples were from stage T3-T4 tumors, and the proportion of FOXC2-positive tumors in each group was 28.5% (53/186) and 20.2% (17/84), respectively.